Article Preview
TopIntroduction
Existing commercial prosthetic heart valve designs can be classified into two groups: bioprosthetic, or tissue valves, and mechanical heart valves. The former is made from a combination of synthetic materials and chemically treated animal tissue mainly porcine in origin, whereas the latter is manufactured entirely from synthetic materials. In the 1960s, Dr Charles Hufnagel performed one of the earliest successful mechanical heart valve surgeries where six of the eight patients who received a caged ball heart valve survived the operation (Hufnagel, Gillespie, Conrad, Mercier, & Evangelist, 1966). However, current artificial heart valves are still exposed to risks of thrombosis and thromboembolism, tissue overgrowth, infection, anti-coagulant related hemorrhage, and valve failure due to material fatigue or chemical change (Black, & Drury, 1994; Yoganathan, 2000; Starr, Fessler, Grunkemeier, & He, 2002; Korossis, Fisher, & Ingham, 2000).
One major drawbacks associated with the implantation of mechanical heart valves is the need for daily chronic anticoagulation therapy to reduce the risk of thrombosis and thromboembolic complications. These patients are expose to an increased risk of bleeding, infection, and/or autoimmune response (Walker, & Yoganathan, 1992). Blood flow through mechanical prostheses can lead to high turbulent stresses that may damage and/or activate blood elements and initiate platelet aggregation. Platelet aggregation can lead to thrombus formation with disastrous consequences for the patient. Thrombi may even detach from the valve and become lodged in a downstream blood vessel, thus reducing or even cutting off the blood supply to vital tissues.
An alternative to mechanical valves is using tissue valves which utilize the concept of a trileaflet configuration with one central orifice that mimics the design of the native valve. These valves have a lower potential for blood element damage than their mechanical counterparts. Nevertheless, the mechanical properties of tissue valves appear to degrade more rapidly, and they are prone to calcification (Black & Drury, 1994). Often, implanted tissue valves do not last for more than ten years, and reoperation is necessary.
The polyurethane (PU) trileaflet polymeric heart valve is the latest development in prosthetic heart valve research (Hyde, Chinn, & Phillips, 1999). The design is based on the natural aortic valve and is inherently appealing from a hemodynamic viewpoint. Although this particular valve design is still in a developmental stage, preliminary studies have shown excellent forward flow hemodynamic properties equivalent to that of a tissue heart valve and promise a durability comparable to that of a mechanical heart valve (Bernacca, Mackay, Wilkinson, & Wheatley, 1995; Jansen et al., 1991). However, recent animal trials involving polymeric valves have reported problems mainly related to tearing of the leaflets and thrombus formation occuring along the stent region of the valve (Wheatley et al., 2001). In addition, results of long-term in vivo evaluation have suggested that calcification could be a limiting factor to long-term function of polymeric valves (Bodnar & Frater, 1991). The leaflets and basal attachments, such as the commissural region of the polymer valves, have experienced extrinsic calcification associated with surface microthrombi that appear to be independent of structural defects suggesting that the flow characteristics inside the polymeric valve may be a contributor to the observed blood clots.
This review will discuss the recent development of polymeric heart valves, particularly on its choice of materials. Much attention will also focus on the in vitro hemodynamics characterization these polymeric heart valves. The review will also discuss the in vivo experiments involving these polymeric heart valves and their susceptibility to calcifications.